Latest news with #SVS
Cision Canada
4 days ago
- Business
- Cision Canada
Graham Rosenberg Proposed Sale of Shares
TORONTO, June 6, 2025 /CNW/ - Graham Rosenberg (the "Selling Shareholder"), the Chief Executive Officer and Chairman of the Board of dentalcorp Holdings Ltd. (the "Company"), announces that he has filed a notice of intention to distribute securities in connection with the his intention to sell, directly or indirectly, up to 477,700 subordinate voting shares of the Company ("SVS"), 450,000 of which will be issued upon the conversion of multiple voting shares of the Company ("MVS" and together with the SVS, the "Shares") in accordance with their terms (the "Sale"). After the Sale, Mr. Rosenberg will, directly or indirectly, retain over 95% of his securities in the Company, including 100% of the Company's issued and outstanding MVS. Mr. Rosenberg plans to use the proceeds from the Sale for tax, financial and estate planning purposes. A copy of the Form 45-102F1 – Notice of Intention to Distribution Securities under Section 2.8 of National Instrument 45-102 – Resale of Securities filed by the Selling Shareholder is available under the Company's profile on the System for Electronic Document Analysis and Retrieval + ("SEDAR+") at There is no assurance as to the timing of the proposed transactions thereunder nor whether any such transactions will occur. Required Early Warning Disclosure This additional disclosure is being provided pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which also requires a report to be filed by GR BCM2 #2 Acquisition Limited Partnership (the "Partnership") with the regulatory authorities in each jurisdiction in which the Company is a reporting issuer containing information with respect to the conversion of MVS to SVS in accordance with their terms (the "Conversion") to be completed in connection with the Sale (the "Early Warning Report"). Prior to the Conversion, Mr. Rosenberg, directly or indirectly, through entities owned and/or controlled, directly or indirectly by him, including the Partnership (the "Rosenberg Group"), held 8,704,535 MVS, representing 100% of the issued and outstanding MVS or 31.5% of the votes attached to all of the Company's issued and outstanding Shares, and 93,774 SVS, representing 0.05% of the issued and outstanding SVS or 0.03% of the votes attached to all of the Company's issued and outstanding Shares. In addition, Mr. Rosenberg held 168,582 restricted share units ("RSUs"), 225,629 performance share units ("PSUs") and 2,750,000 options ("Options"), each exercisable or settled for SVS. Following the Conversion, the Rosenberg Group held 8,254,535 MVS, representing 100% of the issued and outstanding MVS or 30.3% of the votes attached to all of the Company's issued and outstanding Shares, and 543,774 SVS, representing 0.29% of the issued and outstanding SVS or 0.20% of the votes attached to all of the Company's issued and outstanding Shares. Mr. Rosenberg intends to sell, directly or indirectly through the Partnership, up to 477,700 SVS pursuant to the Sale. In addition, Mr. Rosenberg continues to hold 168,582 RSUs, 225,629 PSUs and 2,750,000 Options, each exercisable or settled for SVS. Each MVS represents ten votes on all matters upon which holders of shares in the capital of the Company are entitled to vote and is convertible into one SVS at any time at the sole option of the holder. In addition to the Sale, the Rosenberg Group may, depending on market conditions, acquire additional SVS or dispose of MVS or SVS in the future whether in transactions over the open market or through privately negotiated arrangements or otherwise, subject to a number of factors, including general market conditions and investment diversification. The Company's head office is located at 181 Bay Street, Suite 2600, Toronto, Ontario, M5J 2T3. A copy of the Early Warning Report will be filed under the Company's profile on SEDAR+. The head office of the Selling Shareholder is 181 Bay Street, Suite 2600 Toronto, Ontario M5J 2T3.
Associated Press
4 days ago
- Business
- Associated Press
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ('enVVeno' or the 'Company'), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. 'These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options,' said Robert Berman, enVVeno Medical's Chief Executive Officer. 'Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option.' Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, 'Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve' today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the 'Company') related thereto contain, or may contain, among other things, certain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as 'projects,' 'may,' 'will,' 'could,' 'would,' 'should,' 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'potential' or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLC [email protected] (908) 824-0775 MEDIA CONTACT: Glenn Silver, FINN Partners [email protected] (973) 818-8198 SOURCE: enVVeno Medical Corporation press release
Yahoo
6 days ago
- Business
- Yahoo
MolecuLight to Showcase Innovative Wound Imaging Platform at the Society for Vascular Surgery Vascular Annual Meeting (VAM) 2025
PITTSBURGH, June 4, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, is pleased to announce its participation in the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM), taking place in New Orleans, LA, from June 4-7, 2025. MolecuLight will be exhibiting at Booth #654, showcasing its DX™ device that provides clinicians with real-time insights into wound characteristics, including bacterial presence, digital wound measurement, and recently released thermal imaging to visualize temperature changes. The SVS Vascular Annual Meeting is a premier global event for vascular surgeons and healthcare professionals dedicated to advancing the field of vascular health. MolecuLight's technology aligns with this mission by offering objective, evidence-based data that empowers clinicians to make more informed decisions at the point-of-care for improved patient care and outcomes1,2. In addition to its presence on the exhibition floor, MolecuLight is proud to highlight that Dr. Alisha Oropallo has received the Society for Vascular Surgery Section on Ambulatory Vascular Care (SAVC) Presentation Award for her abstract titled, "An objective comparative study of non-surgical cleansing techniques and cleanser types in bacterial burden management." Dr. Oropallo will be presenting her award-winning research during the VAM SAVC session on Friday, June 6th. This study emphasizes the importance of objective assessment in wound care and aligns with MolecuLight's commitment to providing clinicians with the tools they need for effective bacterial burden management. "We are excited to participate in the SVS Vascular Annual Meeting and connect with leading vascular surgeons," said Anil Amlani, CEO of MolecuLight. "We congratulate Dr. Oropallo on this well-deserved recognition and are proud that her research, highlighting the critical need for objective data in wound care, will be presented at this prestigious meeting." Attendees of the SVS Vascular Annual Meeting are invited to visit MolecuLight at Booth #654 to learn more about their DX device and how MolecuLight's innovative wound imaging platform can elevate efficiency in their clinical practice. About the Society for Vascular Surgery (SVS) Vascular Annual Meeting:The Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM) is the premier international forum for vascular surgeons and other healthcare professionals dedicated to the science, diagnosis, and treatment of vascular disease. This annual event brings together leading experts from around the globe to share the latest research, advancements, and best practices in vascular care. VAM provides a comprehensive educational experience through scientific sessions, interactive workshops, and networking opportunities, all aimed at improving patient outcomes and advancing the field of vascular surgery. About MolecuLight Corp:MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. 1 Jacob A, Jones LM, Abdo RJ, et al. Lights, fluorescence, action-Influencing wound treatment plans including debridement of bacteria and biofilms. Int Wound J. 2023 Oct;20(8):3279-3288. 2 Rahma S, Woods J, Brown S, et al. The Use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial. Diabetes Care. 2022 Jul 7;45(7):1601-1609. View original content to download multimedia: SOURCE MolecuLight Corp.
Yahoo
27-05-2025
- Business
- Yahoo
Sprouts Farmers Market Stock Nears 2 Bullish Trendlines
Grocery chain Sprouts Farmers Market Inc (NASDAQ:SFM) has been chopping higher over the past year, doubling since last May and up 30% in 2025. However, last week, the moved back toward the $160 floor. This dip pushed SFM within one standard deviation of the historically bullish 50-day and 80-day moving averages. Per Schaeffer's Senior Quantitative Analyst Rocky White, SFM has made seven similar approaches to the 50-day trendline and five to the 80-day trendline over the past three years. The stock was higher one month later 71% of the time following the former signal, and 100% following the latter, averaging gains of 6.3% and 7.8%, respectively. A comparable move from SFM's current perch of $164.65 would put the shares as high as $177 by the end of June. The stock has plenty of room for upgrades as well. Heading into today, nine of the 14 analysts in coverage sport a tepid "hold" recommendation. Meanwhile, options are looking like an affordable way to go. This is per SFM's Schaeffer's Volatility Index (SVI) of 36%, which sits in the 23rd percentile of its annual range. Plus, the security's Schaeffer's Volatility Scorecard (SVS) sits at a higher 82 out of 100, meaning it has outperformed options traders' volatility expectations over the past year. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-04-2025
- Business
- Yahoo
Interactive Brokers Stock Boasts Technical Support
Stocks are quite volatile today as investors contend with the latest and speculate over a bottom to the recent selloff. Within this context, shares of Interactive Brokers Group Inc (NASDAQ:IBKR) are down 2.8% at $141.95, and trading at their lowest level since October. For those looking for buy the dip, IBKR has potential has bullish potential. The stock is trading in the vicinity of long-term support at its 320-day moving average today, which also happens to be a historically bullish trendline. Per Schaeffer's Senior Quantitative Analyst Rocky White, the security is within 0.75 of the trendline's 20-day average true range (ATR) for the first time in at least eight of the last 10 trading days, after spending at least 75% of the last six months above it. Within these parameters, three other signals occurred in the past three years. IBKR was higher one month later after each one of these events, averaging a healthy 10.4% gain. The equity is also holding on to a 27.8% year-over-year gain, and has outperformed options traders' volatility expectations over the past year. This is per its Schaeffer's Volatility Scorecard (SVS) of 88 out of 100.
